{"nctId":"NCT00423085","briefTitle":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","startDateStruct":{"date":"2007-01"},"conditions":["Alzheimer's Disease"],"count":859,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"rivastigmine 5 cm^2","type":"EXPERIMENTAL","interventionNames":["Drug: Rivastigmine transdermal patch"]},{"label":"Rivastigmine 10 cm^2","type":"EXPERIMENTAL","interventionNames":["Drug: Rivastigmine transdermal patch"]}],"interventions":[{"name":"Rivastigmine transdermal patch","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria\n* A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria\n* An MMSE score of \\> or = 10 and \\< or = 20\n\nExclusion Criteria:\n\n* A current DSM-IV diagnosis of major depression\n* Taken rivastigmine in the past\n* A score of \\> 5 on the Modified Hachinski Ischemic Scale (MHIS) Other protocol-defined inclusion/exclusion criteria may apply\n\nOther protocol-defined inclusion/exclusion criteria may apply\n\nExtension Phase Eligibility Criteria\n\nInclusion Criteria:\n\n* Patients who have completed the Double-blind Treatment Phase on study medication\n\nExclusion Criteria\n\n* Patients who have any important protocol deviations until the completion of the Double-blind Treatment Phase","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)","description":"The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"9.46"},{"groupId":"OG001","value":"25.2","spread":"9.62"},{"groupId":"OG002","value":"25.0","spread":"9.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"11.49"},{"groupId":"OG001","value":"25.7","spread":"11.70"},{"groupId":"OG002","value":"25.1","spread":"11.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"5.07"},{"groupId":"OG001","value":"0.5","spread":"4.96"},{"groupId":"OG002","value":"0.1","spread":"5.04"}]}]}]},{"type":"PRIMARY","title":"Overall Clinical Rating of Change From Baseline to Week 24 Measured by the Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)","description":"The overall clinical rating of change from baseline to week 24 measured by the 7-point CIBIC plus-J scale. The Clinician's Interview-Based Impression of Change plus Caregiver Input consists of 3 subscales: Disability Assessment of Dementia Scale, Behavioral Pathology in Alzheimer's Disease Rating Scale and Mental Function Impairment Scale, as well as the Clinician's Global Impression of Change (CGIC). Participants are scored according to the following:\n\n1. Markedly improved\n2. Moderately improved\n3. Minimally improved\n4. Unchanged\n5. Minimally worse\n6. Moderately worse\n7. Markedly worse","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)","description":"The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living (ADL). The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in ADL while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.70","spread":"19.902"},{"groupId":"OG001","value":"64.19","spread":"20.571"},{"groupId":"OG002","value":"64.15","spread":"21.921"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.54","spread":"22.395"},{"groupId":"OG001","value":"61.19","spread":"22.415"},{"groupId":"OG002","value":"62.27","spread":"23.691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.16","spread":"12.443"},{"groupId":"OG001","value":"-2.99","spread":"10.259"},{"groupId":"OG002","value":"-1.88","spread":"10.657"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CIBIC Plus-J Score Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)","description":"BEHAVE-AD was used to assess patient behavior and psychiatric symptoms. It covers symptoms in seven categories: paranoid and delusional ideation, hallucinations, activity disturbances, diurnal rhythm disturbances, aggressiveness, affective disorders and anxieties, and phobias. Caregivers rate behavioral symptoms on a 0-3 scale. The total score can range from 0 to 66, with a lower score indicating better function. A negative change score indicates an improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"4.50"},{"groupId":"OG001","value":"4.7","spread":"4.96"},{"groupId":"OG002","value":"5.4","spread":"5.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"5.41"},{"groupId":"OG001","value":"4.6","spread":"5.03"},{"groupId":"OG002","value":"5.1","spread":"5.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.76"},{"groupId":"OG001","value":"-0.1","spread":"4.17"},{"groupId":"OG002","value":"-0.3","spread":"4.70"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CIBIC Plus-J Score Mental Function Impairment Scale (MENFIS)","description":"MENFIS was used to assess patient cognitive and psychiatric function, and evaluates core symptoms of dementia including cognitive, motivational and emotional aspects. The total score ranges from 0 to 78. The higher the score, the greater the functional deficit. A negative change score indicates an improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"11.13"},{"groupId":"OG001","value":"24.3","spread":"11.72"},{"groupId":"OG002","value":"24.6","spread":"11.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"12.68"},{"groupId":"OG001","value":"26.5","spread":"13.43"},{"groupId":"OG002","value":"26.2","spread":"12.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"6.18"},{"groupId":"OG001","value":"2.2","spread":"5.86"},{"groupId":"OG002","value":"1.6","spread":"5.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mini-Mental State Examination (MMSE)","description":"The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"2.87"},{"groupId":"OG001","value":"16.9","spread":"2.88"},{"groupId":"OG002","value":"16.4","spread":"3.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"4.21"},{"groupId":"OG001","value":"16.6","spread":"4.62"},{"groupId":"OG002","value":"16.4","spread":"4.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.82"},{"groupId":"OG001","value":"-0.3","spread":"3.05"},{"groupId":"OG002","value":"0.0","spread":"2.87"}]}]}]},{"type":"SECONDARY","title":"Extension Phase: Change From Extension Phase Baseline to End of Extension in Mini-Mental State Examination (MMSE)","description":"The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement. This outcome measured the change in MMSE from the beginning of the open-label extension phase through to Week 52 of the extension phase.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"4.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"5.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"3.28"}]}]}]},{"type":"SECONDARY","title":"Extension Phase: Change From Extension Phase Baseline to End of Extension in CIBIC Plus-J Score Disability Assessment for Dementia (DAD)","description":"The Disability Assessment for Dementia (DAD) was used to assess levels of difficulty in activities of daily living. The DAD is administered through an interview with the caregiver. A total score is obtained by adding the rating for each question and converting this to a total score out of 100 (%). Higher scores represent less disability in activities of daily living while lower scores indicate more dysfunction. A positive change score indicates an improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.99","spread":"22.939"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.95","spread":"25.407"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.04","spread":"14.089"}]}]}]},{"type":"SECONDARY","title":"Extension Phase: Change From Extension Phase Baseline to End of Extension in Modified Crichton Scale","description":"The Modified Crichton Scale includes a total of seven items evaluated in eight grades that assess basic activities of daily living, communication functions, psychiatric symptoms and quality of life; the total score can range from 0 to 56, with a lower score indicating better function. A negative change score indicates an improvement from baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":"10.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"11.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"6.74"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":286},"commonTop":["Application site erythema","Application site pruritus","Dermatitis contact","Nasopharyngitis","Application site oedema"]}}}